Yahoo Finance Innoviva And Other Great Growth Stocks
Analysts are bullish on these following companies: Innoviva, Jazz Pharmaceuticals, Cardlytics. These companies are relatively strong financially, and have a great outlook in terms of profits and cash flow. Analysing the most recent financial data, I’ve created a list of companies that compare favourably in all criteria, making them potentially good additions to your portfolio.
Innoviva, Inc. (NASDAQ:INVA)
Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Innoviva was founded in 1996 and with the market cap of USD $1.44B, it falls under the small-cap group.
Driven by the positive double-digit sales growth of 28.79% over the next few years, INVA is expected to deliver an excellent earnings growth of 24.67%. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 323.48%. INVA ticks the boxes for robust growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Interested to learn more about INVA? Check out its fundamental factors here.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company provides employment to 1230 people and has a market cap of USD $10.76B, putting it in the large-cap group.
JAZZ is expected to deliver an extremely high earnings growth over the next couple of years of 21.41%, driven by a positive double-digit revenue growth of 31.21% and cost-cutting initiatives. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 22.73%. JAZZ’s impressive outlook on all aspects makes it a worthy company to spend more time to understand. Considering JAZZ as a potential investment? Have a browse through its key fundamentals here.
Cardlytics, Inc. (NASDAQ:CDLX)
Cardlytics, Inc. operates a purchase intelligence platform in the United States and the United Kingdom. Started in 2008, and headed by CEO Scott Grimes, the company provides employment to 345 people and with the company’s market cap sitting at USD $495.46M, it falls under the small-cap stocks category.
Driven by the exceptional 94.25% sales growth over the next few years, CDLX is expected to deliver an excellent earnings growth of 74.77%. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. CDLX ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Want to know more about CDLX? I recommend researching its fundamentals here.
For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.
